Abstract:RIG-I-like receptors (RLRs) are intracellular pattern recognition receptors that detect viral or bacterial infection and induce host innate immune responses. The RLRs family comprises retinoic acid-inducible gene 1 (RIG-I), melanoma differentiation-associated gene 5 (MDA5) and laboratory of genetics and physiology 2 (LGP2) that have distinctive features. These receptors not only recognize RNA intermediates from viruses and bacteria, but also interact with endogenous RNA such as the mislocalized mitochondrial RNA, the aberrantly reactivated repetitive or transposable elements in the human genome. Evasion of RLRs-mediated immune response may lead to sustained infection, defective host immunity and carcinogenesis. Therapeutic targeting RLRs may not only provoke anti-infection effects, but also induce anticancer immunity or sensitize "immune-cold" tumors to immune checkpoint blockade. In this review, we summarize the current knowledge of RLRs signaling and discuss the rationale for therapeutic targeting RLRs in cancer. We describe how RLRs can be activated by synthetic RNA, oncolytic viruses, viral mimicry and radio-chemotherapy, and how the RNA agonists of RLRs can be systemically delivered in vivo. The integration of RLRs agonism with RNA interference or CAR-T cells provides new dimensions that complement cancer immunotherapy. Moreover, we update the progress of recent clinical trials for cancer therapy involving RLRs activation and immune modulation. Further studies of the mechanisms underlying RLRs signaling will shed new light on the development of cancer therapeutics. Manipulation of RLRs signaling represents an opportunity for clinically relevant cancer therapy. Addressing the challenges in this field will help develop future generations of cancer immunotherapy.

The lncRNAs involved in regulating the RIG-I signaling pathway

MicroRNAs in the Regulation of RIG-I-like Receptor Signaling Pathway: Possible Strategy for Viral Infection and Cancer

LncNSPL facilitates influenza A viral immune escape by restricting TRIM25-mediated K63-linked RIG-I ubiquitination

The Triangle Relationship Between Long Noncoding RNA, RIG-I-like Receptor Signaling Pathway, and Glycolysis

Long Non-coding RNAs: Regulators of Viral Infection and the Interferon Antiviral Response

Long Noncoding RNAs, New Critical Regulators in Cancer Immunity.

Regulation of RIG-I-like receptor-mediated signaling: interaction between host and viral factors

The long noncoding RNA Lnczc3h7a promotes a TRIM25-mediated RIG-I antiviral innate immune response

A Long Non-coding RNA IVRPIE Promotes Host Antiviral Immune Responses Through Regulating Interferon β1 and ISG Expression

Self-Recognition of an Inducible Host lncRNA by RIG-I Feedback Restricts Innate Immune Response

Advances of long non-coding RNAs in antiviral innate immunity

RIG-I-like receptors: their regulation and roles in RNA sensing

Exploiting RIG-I-like receptor pathway for cancer immunotherapy

Long non-coding RNAs and immune cells: Unveiling the role in viral infections

Host and Viral Modulation of RIG-I-Mediated Antiviral Immunity

Regulation of PD-1/PD-L1 Pathway in Cancer by Noncoding RNAs

The regulation of lncRNAs and miRNAs in SARS-CoV-2 infection

RDUR, a lncRNA, Promotes Innate Antiviral Responses and Provides Feedback Control of NF-κB Activation

Reciprocal regulation of RIG-I and XRCC4 connects DNA repair with RIG-I immune signaling

Retinoic acid inducible gene-I, more than a virus sensor

Advance of Immunoregulatory Mechanisms of Long Non-Coding Rna